Global Anti-VEGF Intravitreal Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Anti-VEGF intravitreal drugs refer to a class of medications used in ophthalmology to treat various eye conditions characterized by abnormal blood vessel growth and leakage,notably wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,which work by blocking VEGF.These medications help reduce the growth of abnormal blood vessels,decrease vascular leakage, and thereby stabilize or improve vision.
The global Anti-VEGF Intravitreal Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Intravitreal Drugs Industry Forecast” looks at past sales and reviews total world Anti-VEGF Intravitreal Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Intravitreal Drugs sales for 2024 through 2030. With Anti-VEGF Intravitreal Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Intravitreal Drugs industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Intravitreal Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Intravitreal Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Intravitreal Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Intravitreal Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Intravitreal Drugs.
United States market for Anti-VEGF Intravitreal Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Intravitreal Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Intravitreal Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Intravitreal Drugs players cover Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Intravitreal Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Anti-VEGF Intravitreal Drugs market?
What factors are driving Anti-VEGF Intravitreal Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Intravitreal Drugs market opportunities vary by end market size?
How does Anti-VEGF Intravitreal Drugs break out by Type, by Application?
Anti-VEGF intravitreal drugs refer to a class of medications used in ophthalmology to treat various eye conditions characterized by abnormal blood vessel growth and leakage,notably wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,which work by blocking VEGF.These medications help reduce the growth of abnormal blood vessels,decrease vascular leakage, and thereby stabilize or improve vision.
The global Anti-VEGF Intravitreal Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Intravitreal Drugs Industry Forecast” looks at past sales and reviews total world Anti-VEGF Intravitreal Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Intravitreal Drugs sales for 2024 through 2030. With Anti-VEGF Intravitreal Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Intravitreal Drugs industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Intravitreal Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Intravitreal Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Intravitreal Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Intravitreal Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Intravitreal Drugs.
United States market for Anti-VEGF Intravitreal Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Intravitreal Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Intravitreal Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Intravitreal Drugs players cover Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Intravitreal Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Ranibizumab
- Aflibercept
- Conbercept
- Brolucizumab
- Faricimab
- Other
- Age-related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Novartis
- Biogen
- Coherus BioSciences
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Biocon Biologics
- Qilu Pharma
- Chengdu Kanghong Pharmaceutical
What is the 10-year outlook for the global Anti-VEGF Intravitreal Drugs market?
What factors are driving Anti-VEGF Intravitreal Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Intravitreal Drugs market opportunities vary by end market size?
How does Anti-VEGF Intravitreal Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Intravitreal Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Intravitreal Drugs by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Intravitreal Drugs Segment by Type
2.2.1 Ranibizumab
2.2.2 Aflibercept
2.2.3 Conbercept
2.2.4 Brolucizumab
2.2.5 Faricimab
2.2.6 Other
2.3 Anti-VEGF Intravitreal Drugs Sales by Type
2.3.1 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Intravitreal Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Type (2019-2024)
2.4 Anti-VEGF Intravitreal Drugs Segment by Application
2.4.1 Age-related Macular Degeneration
2.4.2 Diabetic Macular Edema
2.4.3 Retinal Vein Occlusion
2.4.4 Other
2.5 Anti-VEGF Intravitreal Drugs Sales by Application
2.5.1 Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Intravitreal Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Intravitreal Drugs Breakdown Data by Company
3.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Intravitreal Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Intravitreal Drugs Product Location Distribution
3.4.2 Players Anti-VEGF Intravitreal Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF INTRAVITREAL DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Intravitreal Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Intravitreal Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Intravitreal Drugs Sales Growth
4.4 APAC Anti-VEGF Intravitreal Drugs Sales Growth
4.5 Europe Anti-VEGF Intravitreal Drugs Sales Growth
4.6 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Intravitreal Drugs Sales by Country
5.1.1 Americas Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
5.3 Americas Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Intravitreal Drugs Sales by Region
6.1.1 APAC Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
6.3 APAC Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Intravitreal Drugs by Country
7.1.1 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
7.3 Europe Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Intravitreal Drugs by Country
8.1.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs
10.3 Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
10.4 Industry Chain Structure of Anti-VEGF Intravitreal Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Intravitreal Drugs Distributors
11.3 Anti-VEGF Intravitreal Drugs Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF INTRAVITREAL DRUGS BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Intravitreal Drugs Market Size Forecast by Region
12.1.1 Global Anti-VEGF Intravitreal Drugs Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Anti-VEGF Intravitreal Drugs Forecast by Type (2025-2030)
12.7 Global Anti-VEGF Intravitreal Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.2.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Biogen
13.3.1 Biogen Company Information
13.3.2 Biogen Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.3.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Biogen Main Business Overview
13.3.5 Biogen Latest Developments
13.4 Coherus BioSciences
13.4.1 Coherus BioSciences Company Information
13.4.2 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Coherus BioSciences Main Business Overview
13.4.5 Coherus BioSciences Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Samsung Bioepis
13.6.1 Samsung Bioepis Company Information
13.6.2 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Samsung Bioepis Main Business Overview
13.6.5 Samsung Bioepis Latest Developments
13.7 Biocon Biologics
13.7.1 Biocon Biologics Company Information
13.7.2 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Biocon Biologics Main Business Overview
13.7.5 Biocon Biologics Latest Developments
13.8 Qilu Pharma
13.8.1 Qilu Pharma Company Information
13.8.2 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Qilu Pharma Main Business Overview
13.8.5 Qilu Pharma Latest Developments
13.9 Chengdu Kanghong Pharmaceutical
13.9.1 Chengdu Kanghong Pharmaceutical Company Information
13.9.2 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chengdu Kanghong Pharmaceutical Main Business Overview
13.9.5 Chengdu Kanghong Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Anti-VEGF Intravitreal Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Intravitreal Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Aflibercept
Table 5. Major Players of Conbercept
Table 6. Major Players of Brolucizumab
Table 7. Major Players ofFaricimab
Table 8. Major Players of Other
Table 9. Global Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 10. Global Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Table 11. Global Anti-VEGF Intravitreal Drugs Revenue byType (2019-2024) & ($ million)
Table 12. Global Anti-VEGF Intravitreal Drugs Revenue Market Share byType (2019-2024)
Table 13. Global Anti-VEGF Intravitreal Drugs Sale Price byType (2019-2024) & (US$/Dose)
Table 14. Global Anti-VEGF Intravitreal Drugs Sale by Application (2019-2024) & (K Dose)
Table 15. Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2019-2024)
Table 16. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2019-2024) & ($ million)
Table 17. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2019-2024)
Table 18. Global Anti-VEGF Intravitreal Drugs Sale Price by Application (2019-2024) & (US$/Dose)
Table 19. Global Anti-VEGF Intravitreal Drugs Sales by Company (2019-2024) & (K Dose)
Table 20. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company (2019-2024)
Table 21. Global Anti-VEGF Intravitreal Drugs Revenue by Company (2019-2024) & ($ millions)
Table 22. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company (2019-2024)
Table 23. Global Anti-VEGF Intravitreal Drugs Sale Price by Company (2019-2024) & (US$/Dose)
Table 24. Key Manufacturers Anti-VEGF Intravitreal Drugs Producing Area Distribution and Sales Area
Table 25. Players Anti-VEGF Intravitreal Drugs Products Offered
Table 26. Anti-VEGF Intravitreal Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Anti-VEGF Intravitreal Drugs Sales by Geographic Region (2019-2024) & (K Dose)
Table 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share Geographic Region (2019-2024)
Table 31. Global Anti-VEGF Intravitreal Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Anti-VEGF Intravitreal Drugs Sales by Country/Region (2019-2024) & (K Dose)
Table 34. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2019-2024)
Table 35. Global Anti-VEGF Intravitreal Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
Table 38. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2024)
Table 39. Americas Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & ($ millions)
Table 40. Americas Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 41. Americas Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 42. APAC Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024) & (K Dose)
Table 43. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2019-2024)
Table 44. APAC Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024) & ($ millions)
Table 45. APAC Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 46. APAC Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 47. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
Table 48. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & ($ millions)
Table 49. Europe Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 50. Europe Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 51. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
Table 52. Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
Table 53. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 54. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 55. Key Market Drivers & Growth Opportunities of Anti-VEGF Intravitreal Drugs
Table 56. Key Market Challenges & Risks of Anti-VEGF Intravitreal Drugs
Table 57. Key IndustryTrends of Anti-VEGF Intravitreal Drugs
Table 58. Anti-VEGF Intravitreal Drugs Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Anti-VEGF Intravitreal Drugs Distributors List
Table 61. Anti-VEGF Intravitreal Drugs Customer List
Table 62. Global Anti-VEGF Intravitreal Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 63. Global Anti-VEGF Intravitreal Drugs RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Americas Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Americas Anti-VEGF Intravitreal Drugs Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. APAC Anti-VEGF Intravitreal Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 67. APAC Anti-VEGF Intravitreal Drugs Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 68. Europe Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 69. Europe Anti-VEGF Intravitreal Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 70. Middle East & Africa Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 71. Middle East & Africa Anti-VEGF Intravitreal Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 72. Global Anti-VEGF Intravitreal Drugs SalesForecast byType (2025-2030) & (K Dose)
Table 73. Global Anti-VEGF Intravitreal Drugs RevenueForecast byType (2025-2030) & ($ millions)
Table 74. Global Anti-VEGF Intravitreal Drugs SalesForecast by Application (2025-2030) & (K Dose)
Table 75. Global Anti-VEGF Intravitreal Drugs RevenueForecast by Application (2025-2030) & ($ millions)
Table 76. Roche Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 77. Roche Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 78. Roche Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 79. Roche Main Business
Table 80. Roche Latest Developments
Table 81. Novartis Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 83. Novartis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 84. Novartis Main Business
Table 85. Novartis Latest Developments
Table 86. Biogen Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Biogen Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 88. Biogen Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 89. Biogen Main Business
Table 90. Biogen Latest Developments
Table 91. Coherus BioSciences Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 93. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 94. Coherus BioSciences Main Business
Table 95. Coherus BioSciences Latest Developments
Table 96. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 98. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 99. Regeneron Pharmaceuticals Main Business
Table 100. Regeneron Pharmaceuticals Latest Developments
Table 101. Samsung Bioepis Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 103. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 104. Samsung Bioepis Main Business
Table 105. Samsung Bioepis Latest Developments
Table 106. Biocon Biologics Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 108. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 109. Biocon Biologics Main Business
Table 110. Biocon Biologics Latest Developments
Table 111. Qilu Pharma Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 113. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 114. Qilu Pharma Main Business
Table 115. Qilu Pharma Latest Developments
Table 116. Chengdu Kanghong Pharmaceutical Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 118. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 119. Chengdu Kanghong Pharmaceutical Main Business
Table 120. Chengdu Kanghong Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture of Anti-VEGF Intravitreal Drugs
Figure 2. Anti-VEGF Intravitreal Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Intravitreal Drugs Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Anti-VEGF Intravitreal Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Anti-VEGF Intravitreal Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2023)
Figure 10. Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Ranibizumab
Figure 12. Product Picture of Aflibercept
Figure 13. Product Picture of Conbercept
Figure 14. Product Picture of Brolucizumab
Figure 15. Product Picture ofFaricimab
Figure 16. Product Picture of Other
Figure 17. Global Anti-VEGF Intravitreal Drugs Sales Market Share byType in 2023
Figure 18. Global Anti-VEGF Intravitreal Drugs Revenue Market Share byType (2019-2024)
Figure 19. Anti-VEGF Intravitreal Drugs Consumed in Age-related Macular Degeneration
Figure 20. Global Anti-VEGF Intravitreal Drugs Market: Age-related Macular Degeneration (2019-2024) & (K Dose)
Figure 21. Anti-VEGF Intravitreal Drugs Consumed in Diabetic Macular Edema
Figure 22. Global Anti-VEGF Intravitreal Drugs Market: Diabetic Macular Edema (2019-2024) & (K Dose)
Figure 23. Anti-VEGF Intravitreal Drugs Consumed in Retinal Vein Occlusion
Figure 24. Global Anti-VEGF Intravitreal Drugs Market: Retinal Vein Occlusion (2019-2024) & (K Dose)
Figure 25. Anti-VEGF Intravitreal Drugs Consumed in Other
Figure 26. Global Anti-VEGF Intravitreal Drugs Market: Other (2019-2024) & (K Dose)
Figure 27. Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2023)
Figure 28. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application in 2023
Figure 29. Anti-VEGF Intravitreal Drugs Sales by Company in 2023 (K Dose)
Figure 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company in 2023
Figure 31. Anti-VEGF Intravitreal Drugs Revenue by Company in 2023 ($ millions)
Figure 32. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company in 2023
Figure 33. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 36. Americas Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 37. APAC Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 38. APAC Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 39. Europe Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 40. Europe Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 41. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 42. Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 43. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Country in 2023
Figure 44. Americas Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
Figure 45. Americas Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 46. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 47. United States Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 48. Canada Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 49. Mexico Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 50. Brazil Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 51. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Region in 2023
Figure 52. APAC Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2019-2024)
Figure 53. APAC Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 54. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 55. China Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. Japan Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 57. South Korea Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 58. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 59. India Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 60. Australia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 61. ChinaTaiwan Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 62. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country in 2023
Figure 63. Europe Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
Figure 64. Europe Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 65. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 66. Germany Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 67.France Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 68. UK Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 69. Italy Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 70. Russia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2024)
Figure 72. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 73. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 74. Egypt Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 75. South Africa Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 76. Israel Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 77.Turkey Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 78. GCC Countries Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs in 2023
Figure 80. Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
Figure 81. Industry Chain Structure of Anti-VEGF Intravitreal Drugs
Figure 82. Channels of Distribution
Figure 83. Global Anti-VEGF Intravitreal Drugs Sales MarketForecast by Region (2025-2030)
Figure 84. Global Anti-VEGF Intravitreal Drugs Revenue Market ShareForecast by Region (2025-2030)
Figure 85. Global Anti-VEGF Intravitreal Drugs Sales Market ShareForecast byType (2025-2030)
Figure 86. Global Anti-VEGF Intravitreal Drugs Revenue Market ShareForecast byType (2025-2030)
Figure 87. Global Anti-VEGF Intravitreal Drugs Sales Market ShareForecast by Application (2025-2030)
Figure 88. Global Anti-VEGF Intravitreal Drugs Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Intravitreal Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Intravitreal Drugs by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Intravitreal Drugs Segment by Type
2.2.1 Ranibizumab
2.2.2 Aflibercept
2.2.3 Conbercept
2.2.4 Brolucizumab
2.2.5 Faricimab
2.2.6 Other
2.3 Anti-VEGF Intravitreal Drugs Sales by Type
2.3.1 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Intravitreal Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Type (2019-2024)
2.4 Anti-VEGF Intravitreal Drugs Segment by Application
2.4.1 Age-related Macular Degeneration
2.4.2 Diabetic Macular Edema
2.4.3 Retinal Vein Occlusion
2.4.4 Other
2.5 Anti-VEGF Intravitreal Drugs Sales by Application
2.5.1 Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Intravitreal Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Intravitreal Drugs Breakdown Data by Company
3.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Intravitreal Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Intravitreal Drugs Product Location Distribution
3.4.2 Players Anti-VEGF Intravitreal Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF INTRAVITREAL DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Intravitreal Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Intravitreal Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Intravitreal Drugs Sales Growth
4.4 APAC Anti-VEGF Intravitreal Drugs Sales Growth
4.5 Europe Anti-VEGF Intravitreal Drugs Sales Growth
4.6 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Intravitreal Drugs Sales by Country
5.1.1 Americas Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
5.3 Americas Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Intravitreal Drugs Sales by Region
6.1.1 APAC Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
6.3 APAC Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Intravitreal Drugs by Country
7.1.1 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
7.3 Europe Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Intravitreal Drugs by Country
8.1.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs
10.3 Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
10.4 Industry Chain Structure of Anti-VEGF Intravitreal Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Intravitreal Drugs Distributors
11.3 Anti-VEGF Intravitreal Drugs Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF INTRAVITREAL DRUGS BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Intravitreal Drugs Market Size Forecast by Region
12.1.1 Global Anti-VEGF Intravitreal Drugs Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Anti-VEGF Intravitreal Drugs Forecast by Type (2025-2030)
12.7 Global Anti-VEGF Intravitreal Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.2.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Biogen
13.3.1 Biogen Company Information
13.3.2 Biogen Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.3.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Biogen Main Business Overview
13.3.5 Biogen Latest Developments
13.4 Coherus BioSciences
13.4.1 Coherus BioSciences Company Information
13.4.2 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Coherus BioSciences Main Business Overview
13.4.5 Coherus BioSciences Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Samsung Bioepis
13.6.1 Samsung Bioepis Company Information
13.6.2 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Samsung Bioepis Main Business Overview
13.6.5 Samsung Bioepis Latest Developments
13.7 Biocon Biologics
13.7.1 Biocon Biologics Company Information
13.7.2 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Biocon Biologics Main Business Overview
13.7.5 Biocon Biologics Latest Developments
13.8 Qilu Pharma
13.8.1 Qilu Pharma Company Information
13.8.2 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Qilu Pharma Main Business Overview
13.8.5 Qilu Pharma Latest Developments
13.9 Chengdu Kanghong Pharmaceutical
13.9.1 Chengdu Kanghong Pharmaceutical Company Information
13.9.2 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
13.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chengdu Kanghong Pharmaceutical Main Business Overview
13.9.5 Chengdu Kanghong Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Anti-VEGF Intravitreal Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Intravitreal Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Aflibercept
Table 5. Major Players of Conbercept
Table 6. Major Players of Brolucizumab
Table 7. Major Players ofFaricimab
Table 8. Major Players of Other
Table 9. Global Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 10. Global Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Table 11. Global Anti-VEGF Intravitreal Drugs Revenue byType (2019-2024) & ($ million)
Table 12. Global Anti-VEGF Intravitreal Drugs Revenue Market Share byType (2019-2024)
Table 13. Global Anti-VEGF Intravitreal Drugs Sale Price byType (2019-2024) & (US$/Dose)
Table 14. Global Anti-VEGF Intravitreal Drugs Sale by Application (2019-2024) & (K Dose)
Table 15. Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2019-2024)
Table 16. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2019-2024) & ($ million)
Table 17. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2019-2024)
Table 18. Global Anti-VEGF Intravitreal Drugs Sale Price by Application (2019-2024) & (US$/Dose)
Table 19. Global Anti-VEGF Intravitreal Drugs Sales by Company (2019-2024) & (K Dose)
Table 20. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company (2019-2024)
Table 21. Global Anti-VEGF Intravitreal Drugs Revenue by Company (2019-2024) & ($ millions)
Table 22. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company (2019-2024)
Table 23. Global Anti-VEGF Intravitreal Drugs Sale Price by Company (2019-2024) & (US$/Dose)
Table 24. Key Manufacturers Anti-VEGF Intravitreal Drugs Producing Area Distribution and Sales Area
Table 25. Players Anti-VEGF Intravitreal Drugs Products Offered
Table 26. Anti-VEGF Intravitreal Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Anti-VEGF Intravitreal Drugs Sales by Geographic Region (2019-2024) & (K Dose)
Table 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share Geographic Region (2019-2024)
Table 31. Global Anti-VEGF Intravitreal Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Anti-VEGF Intravitreal Drugs Sales by Country/Region (2019-2024) & (K Dose)
Table 34. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2019-2024)
Table 35. Global Anti-VEGF Intravitreal Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
Table 38. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2024)
Table 39. Americas Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & ($ millions)
Table 40. Americas Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 41. Americas Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 42. APAC Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024) & (K Dose)
Table 43. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2019-2024)
Table 44. APAC Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024) & ($ millions)
Table 45. APAC Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 46. APAC Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 47. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
Table 48. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & ($ millions)
Table 49. Europe Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 50. Europe Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 51. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)
Table 52. Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
Table 53. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)
Table 54. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)
Table 55. Key Market Drivers & Growth Opportunities of Anti-VEGF Intravitreal Drugs
Table 56. Key Market Challenges & Risks of Anti-VEGF Intravitreal Drugs
Table 57. Key IndustryTrends of Anti-VEGF Intravitreal Drugs
Table 58. Anti-VEGF Intravitreal Drugs Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Anti-VEGF Intravitreal Drugs Distributors List
Table 61. Anti-VEGF Intravitreal Drugs Customer List
Table 62. Global Anti-VEGF Intravitreal Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 63. Global Anti-VEGF Intravitreal Drugs RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Americas Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Americas Anti-VEGF Intravitreal Drugs Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. APAC Anti-VEGF Intravitreal Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 67. APAC Anti-VEGF Intravitreal Drugs Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 68. Europe Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 69. Europe Anti-VEGF Intravitreal Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 70. Middle East & Africa Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 71. Middle East & Africa Anti-VEGF Intravitreal Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 72. Global Anti-VEGF Intravitreal Drugs SalesForecast byType (2025-2030) & (K Dose)
Table 73. Global Anti-VEGF Intravitreal Drugs RevenueForecast byType (2025-2030) & ($ millions)
Table 74. Global Anti-VEGF Intravitreal Drugs SalesForecast by Application (2025-2030) & (K Dose)
Table 75. Global Anti-VEGF Intravitreal Drugs RevenueForecast by Application (2025-2030) & ($ millions)
Table 76. Roche Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 77. Roche Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 78. Roche Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 79. Roche Main Business
Table 80. Roche Latest Developments
Table 81. Novartis Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 83. Novartis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 84. Novartis Main Business
Table 85. Novartis Latest Developments
Table 86. Biogen Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Biogen Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 88. Biogen Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 89. Biogen Main Business
Table 90. Biogen Latest Developments
Table 91. Coherus BioSciences Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 93. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 94. Coherus BioSciences Main Business
Table 95. Coherus BioSciences Latest Developments
Table 96. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 98. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 99. Regeneron Pharmaceuticals Main Business
Table 100. Regeneron Pharmaceuticals Latest Developments
Table 101. Samsung Bioepis Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 103. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 104. Samsung Bioepis Main Business
Table 105. Samsung Bioepis Latest Developments
Table 106. Biocon Biologics Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 108. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 109. Biocon Biologics Main Business
Table 110. Biocon Biologics Latest Developments
Table 111. Qilu Pharma Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 113. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 114. Qilu Pharma Main Business
Table 115. Qilu Pharma Latest Developments
Table 116. Chengdu Kanghong Pharmaceutical Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
Table 118. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 119. Chengdu Kanghong Pharmaceutical Main Business
Table 120. Chengdu Kanghong Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture of Anti-VEGF Intravitreal Drugs
Figure 2. Anti-VEGF Intravitreal Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Intravitreal Drugs Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Anti-VEGF Intravitreal Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Anti-VEGF Intravitreal Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2023)
Figure 10. Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Ranibizumab
Figure 12. Product Picture of Aflibercept
Figure 13. Product Picture of Conbercept
Figure 14. Product Picture of Brolucizumab
Figure 15. Product Picture ofFaricimab
Figure 16. Product Picture of Other
Figure 17. Global Anti-VEGF Intravitreal Drugs Sales Market Share byType in 2023
Figure 18. Global Anti-VEGF Intravitreal Drugs Revenue Market Share byType (2019-2024)
Figure 19. Anti-VEGF Intravitreal Drugs Consumed in Age-related Macular Degeneration
Figure 20. Global Anti-VEGF Intravitreal Drugs Market: Age-related Macular Degeneration (2019-2024) & (K Dose)
Figure 21. Anti-VEGF Intravitreal Drugs Consumed in Diabetic Macular Edema
Figure 22. Global Anti-VEGF Intravitreal Drugs Market: Diabetic Macular Edema (2019-2024) & (K Dose)
Figure 23. Anti-VEGF Intravitreal Drugs Consumed in Retinal Vein Occlusion
Figure 24. Global Anti-VEGF Intravitreal Drugs Market: Retinal Vein Occlusion (2019-2024) & (K Dose)
Figure 25. Anti-VEGF Intravitreal Drugs Consumed in Other
Figure 26. Global Anti-VEGF Intravitreal Drugs Market: Other (2019-2024) & (K Dose)
Figure 27. Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2023)
Figure 28. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application in 2023
Figure 29. Anti-VEGF Intravitreal Drugs Sales by Company in 2023 (K Dose)
Figure 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company in 2023
Figure 31. Anti-VEGF Intravitreal Drugs Revenue by Company in 2023 ($ millions)
Figure 32. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company in 2023
Figure 33. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 36. Americas Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 37. APAC Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 38. APAC Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 39. Europe Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 40. Europe Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 41. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
Figure 42. Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue 2019-2024 ($ millions)
Figure 43. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Country in 2023
Figure 44. Americas Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
Figure 45. Americas Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 46. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 47. United States Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 48. Canada Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 49. Mexico Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 50. Brazil Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 51. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Region in 2023
Figure 52. APAC Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2019-2024)
Figure 53. APAC Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 54. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 55. China Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. Japan Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 57. South Korea Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 58. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 59. India Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 60. Australia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 61. ChinaTaiwan Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 62. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country in 2023
Figure 63. Europe Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)
Figure 64. Europe Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 65. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 66. Germany Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 67.France Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 68. UK Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 69. Italy Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 70. Russia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2024)
Figure 72. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)
Figure 73. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)
Figure 74. Egypt Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 75. South Africa Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 76. Israel Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 77.Turkey Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 78. GCC Countries Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs in 2023
Figure 80. Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
Figure 81. Industry Chain Structure of Anti-VEGF Intravitreal Drugs
Figure 82. Channels of Distribution
Figure 83. Global Anti-VEGF Intravitreal Drugs Sales MarketForecast by Region (2025-2030)
Figure 84. Global Anti-VEGF Intravitreal Drugs Revenue Market ShareForecast by Region (2025-2030)
Figure 85. Global Anti-VEGF Intravitreal Drugs Sales Market ShareForecast byType (2025-2030)
Figure 86. Global Anti-VEGF Intravitreal Drugs Revenue Market ShareForecast byType (2025-2030)
Figure 87. Global Anti-VEGF Intravitreal Drugs Sales Market ShareForecast by Application (2025-2030)
Figure 88. Global Anti-VEGF Intravitreal Drugs Revenue Market ShareForecast by Application (2025-2030)
